Epothilones and the next generation of phase III trials for prostate cancer
dc.contributor.author | Bhandari, Manish S. | en_US |
dc.contributor.author | Hussain, Maha H. A. | en_US |
dc.date.accessioned | 2010-06-01T18:20:02Z | |
dc.date.available | 2010-06-01T18:20:02Z | |
dc.date.issued | 2005-08 | en_US |
dc.identifier.citation | Bhandari, Manish S.; Hussain, Maha (2005). "Epothilones and the next generation of phase III trials for prostate cancer." BJU International 96(3): 296-302. <http://hdl.handle.net/2027.42/71543> | en_US |
dc.identifier.issn | 1464-4096 | en_US |
dc.identifier.issn | 1464-410X | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/71543 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16042717&dopt=citation | en_US |
dc.format.extent | 174166 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Science Ltd | en_US |
dc.rights | 2005 BJU INTERNATIONAL | en_US |
dc.subject.other | Epothilones | en_US |
dc.subject.other | Chemotherapy | en_US |
dc.subject.other | Hormone-refractory Prostate Cancer | en_US |
dc.title | Epothilones and the next generation of phase III trials for prostate cancer | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | * Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA | en_US |
dc.identifier.pmid | 16042717 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/71543/1/j.1464-410X.2005.05618.x.pdf | |
dc.identifier.doi | 10.1111/j.1464-410X.2005.05618.x | en_US |
dc.identifier.source | BJU International | en_US |
dc.identifier.citedreference | Jemal A, Murray T, Ward E et al. Cancer statistics 2005. CA Cancer J Clin 2005; 55: 10 – 30 | en_US |
dc.identifier.citedreference | Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28: 555 | en_US |
dc.identifier.citedreference | Coen JJ, Zietman AL, Thakral H, Shipley WU. Radical radiation for localized prostate cancer. local persistence of disease results in a late wave of metastases. J Clin Oncol 2002; 20: 3199 | en_US |
dc.identifier.citedreference | Carroll PR, Kantoff PW, Balk SP et al. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology 2002; 60 ( Suppl ): 1 | en_US |
dc.identifier.citedreference | Chodak GW, Keane T, Klotz L. Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology 2002; 60: 201 | en_US |
dc.identifier.citedreference | Kelly Wm, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993; 149: 607 | en_US |
dc.identifier.citedreference | Harris KA, Weinberg V, Bok RA, Kakefuda M, Small E J. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol 2002; 168: 542 | en_US |
dc.identifier.citedreference | Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol, 1997; 15: 382 | en_US |
dc.identifier.citedreference | Petrylak DP, Tangen C, Hussain M et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513 – 20 | en_US |
dc.identifier.citedreference | Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502 – 12 | en_US |
dc.identifier.citedreference | Bhandari MS, Petrylak DP, Hussain M. Clinical trials in metastatic prostate cancer – has there been real progress in the past decade? Eur J Cancer 2005; 41: 941 – 53 | en_US |
dc.identifier.citedreference | Bollag DM, McQueney PA, Zhu J et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995; 55: 2325 – 33 | en_US |
dc.identifier.citedreference | Gerth K, Bedorf N, Hofle G et al. Epothilons A and B. Antifungal and cytotoxic compounds from Sorangium cellulosum ( Myxobacteria ): Production, physico-chemical and biological properties. J Antibiot (Tokyo) 1996; 49: 560 – 3 | en_US |
dc.identifier.citedreference | Lee FY, Borzilleri R, Fairchild CR et al. BMS-247550. a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001; 7: 1429 – 37 | en_US |
dc.identifier.citedreference | Goodin S, Kane MP, Rubin EH. Epothilones. mechanism of action and biological activity. J Clin Oncol 2004; 22: 2015 – 25 | en_US |
dc.identifier.citedreference | Horwitz SB. Mechanism of action of taxol. Trends Pharmacol Sci 1992; 13: 134 – 6 | en_US |
dc.identifier.citedreference | Jordan MA, Toso RJ, Thrower D et al. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993; 90: 9552 – 6 | en_US |
dc.identifier.citedreference | Trielli MO, Andreassen PR, Lacroix FB et al. Differential Taxol-dependent arrest of transformed and nontransformed cells in the G1 phase of the cell cycle, and specific-related mortality of transformed cells. J Cell Biol 1996; 135: 689 – 700 | en_US |
dc.identifier.citedreference | Wahl AF, Donaldson KL, Fairchild C et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Med 1996; 2: 72 – 9 | en_US |
dc.identifier.citedreference | Belotti D, Vergani V, Drudis T et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996; 2: 1843 – 9 | en_US |
dc.identifier.citedreference | Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol). J Biol Chem 1997; 272: 2534 – 41 | en_US |
dc.identifier.citedreference | Nogales E, Wolf SG, Khan IA et al. Structure of tubulin at 6.5 A and location of the taxol-binding site. Nature 1995; 375: 424 – 7 | en_US |
dc.identifier.citedreference | Bode CJ, Gupta ML Jr, Reiff EA et al. Epothilone and paclitaxel: Unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry 2002; 41: 3870 – 4 | en_US |
dc.identifier.citedreference | Giannakakou P, Gussio R, Nogales E et al. A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA 2000; 97: 2904 – 9 | en_US |
dc.identifier.citedreference | Verrills NM, Flemming CL, Liu M et al. Microtubule alterations and mutations induced by desoxyepothilone B. Implications for drug–target interactions. Chem Biol 2003; 10: 597 – 607 | en_US |
dc.identifier.citedreference | Wartmann M, Altmann K-H. The biology and medicinal chemistry of epothilones. Curr Med Chem Anti-Canc Agents 2002; 2: 123 – 48 | en_US |
dc.identifier.citedreference | Hussain M, Faulkner J, Vaishampayan U et al. Epithilone B, (Epo-B) analogue BMS-247550a (NSC 710428) administered every 21 days in patients (pts) with hormone refractory prostate cancer (HRPC). A Southwest Oncology Group Study (S0111). Program and Abstracts of the 40th Annual Meeting of the American Society of Clinical Oncology; June 5–8, 2004. New Orleans, Louisiana. Abstract 4510 | en_US |
dc.identifier.citedreference | Kelly WK, Galsky MD, Small EJ et al. Multi-institutional trial of the epothilone B analogue BMS-247550 with or without estramustine phosphate (EMP) in patients with progressive castrate-metastatic prostate cancer (PCMPC): Updated results. Program and Abstracts of the 40th Annual Meeting of the American Society of Clinical Oncology; June 5–8, 2004; New Orleans, Louisiana. Abstract 4509 | en_US |
dc.identifier.citedreference | Rosenberg JE, Galsky MD, Weinberg V et al. Response to second-line taxane-based therapy after first-line epothilone B analogue BMS 247550 (BMS) therapy in hormone refractory prostate cancer. Abstracts of the ASCO Prostate Cancer Symposium; February 17–19, 2005; Orlando, Florida. Abstract 267 | en_US |
dc.identifier.citedreference | Vanteenkiste JF, Breton JL, Sandler A et al. A randomized phase II study of epothilone analog BMS-247550 in patients with non-small cell lung cancer who have failed first-line platinum-based chemotherapy. Proc Am Soc Clin Oncol 2003; 22: 626 | en_US |
dc.identifier.citedreference | Mekhail T, Chung C, Holden S et al. Phase I trial of novel epothilone B analog BMS-310705 IV q21 days. Proc Am Soc Clin Oncol 2003; 22: 129, A515 | en_US |
dc.identifier.citedreference | Sessa C, Perotti A, Malossi A et al. Phase I and pharmacokinetic study of the novel epothilone BMS-310705 in patients with advanced solid cancer. Proc Am Soc Clin Oncol 2003; 22: 130, A519 | en_US |
dc.identifier.citedreference | Wartmann M, Koppler, J, Larigot M et al. Epothilones A and B accumulate several-hundred fold inside cells. Proc Am Soc Cancer Res 2000; 41: 213, A1362 | en_US |
dc.identifier.citedreference | Hussain A, Dipaola RS, Baron AD et al. A, Phase I. trial of weekly EPO906 in patients with hormone-refractory prostate cancer (HRPC). Program and Abstracts of the 40th Annual Meeting of the American Society of Clinical Oncology; June 5–8, 2004; New Orleans, Louisiana. Abstract 4563 | en_US |
dc.identifier.citedreference | Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003; 3: 110 – 6 | en_US |
dc.identifier.citedreference | Nelson JB, Lee WH, Nguyen SH et al. Methylation of the 5′ CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res 1997; 57: 35 – 7 | en_US |
dc.identifier.citedreference | Mundy GR, Yin JJ, Mohammad KS et al. A. Endothelin-1 and osteoblastic metastasis. Proc Natl Acad Sci USA 2003; 100: 10588 – 9 | en_US |
dc.identifier.citedreference | Yin JJ, Mohammad KS, Kakonen SM et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 2003; 100: 10954 – 9 | en_US |
dc.identifier.citedreference | Nelson JB, Chan-Tack K, Hedican SP et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996; 56: 663 – 8 | en_US |
dc.identifier.citedreference | Papandreou CN, Usmani B, Geng Y et al. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nature Med 1998; 4: 50 – 7 | en_US |
dc.identifier.citedreference | Nelson JB, Hedican SP, George DJ et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nature Med 1995; 1: 944 – 9 | en_US |
dc.identifier.citedreference | Pao MM, Tsutsumi M, Liang G, Uzvolgyi E, Gonzales FA, Jones P. A. The endothelin receptor B (EDNRB) promoter displays heterogeneous, site specific methylation patterns in normal and tumor cells. Hum Mol Genet 2001; 10: 903 – 10 | en_US |
dc.identifier.citedreference | Jeronimo C, Henrique R, Campos PF et al. Endothelin B receptor gene hypermethylation in prostate adenocarcinoma. J Clin Pathol 2003; 56: 52 – 5 | en_US |
dc.identifier.citedreference | Wessale JL, Adler AL, Novosad EI et al. Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: ex vivo and in vivo studies. Clin Sci (Lond) 2002; 103 ( Suppl. 48 ): 112S – 117S | en_US |
dc.identifier.citedreference | Pirtskhalaishvili G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate 2000; 44: 77 – 87 | en_US |
dc.identifier.citedreference | Fizazi K, Yang J, Peleg S et al. Prostate cancer cells–osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res 2003; 9: 2587 – 97 | en_US |
dc.identifier.citedreference | Carducci MA, Padley RJ, Breul J et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003; 21: 679 – 89 | en_US |
dc.identifier.citedreference | Carducci M, Nelson JB, Saad F et al. Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: phase 3 study. Proc Am Soc Clin Oncol 2004; 23: 396, A4508 | en_US |
dc.identifier.citedreference | Nelson JB. Endothelin receptor antagonists. World J Urol 2005; 23: 19 – 27 | en_US |
dc.identifier.citedreference | Rosano L, Spinella F, Salani D et al. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Res 2003; 63: 2447 – 53 | en_US |
dc.identifier.citedreference | Del Bufalo D, Di Castro V, Biroccio A et al. Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. Mol Pharmacol 2002; 61: 524 – 32 | en_US |
dc.identifier.citedreference | Lara PN Jr, Twardowski P, Quinn DI. Angiogenesis-targeted therapies in prostate cancer. Clin Prostate Cancer 2004; 3: 165 – 73 | en_US |
dc.identifier.citedreference | Picus J, Halabi S, Rini BI et al. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): initial results of CALGB 90006. Proc Am Soc Clin Oncol 2004; 22: 1578A | en_US |
dc.identifier.citedreference | Halabi S, Small EJ, Kantoff PW et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21: 1232 – 7 | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.